Evidence map›Paper›PMID 38578808›Full record

ArticlePLoS neglected tropical diseases2024

Protoplast-mediated transformation of Madurella mycetomatis using hygromycin resistance as a selection marker.

Saskia du Pré, Mickey Konings, Dorenda J A Schoorl, Ahmed H Fahal, Mark Arentshorst, Arthur F J Ram, Wendy W J van de Sande

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saskia du PréErasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.
Mickey KoningsErasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.ORCID 0000-0003-3983-4304
Dorenda J A SchoorlErasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.ORCID 0009-0008-2445-2972
Ahmed H FahalMycetoma Research Centre, Khartoum, Sudan.ORCID 0000-0003-4922-7321
Mark ArentshorstMolecular Microbiology and Biotechnology, Institute of Biology Leiden, Leiden University, Leiden, The Netherlands.ORCID 0000-0001-7693-9370
Arthur F J RamMolecular Microbiology and Biotechnology, Institute of Biology Leiden, Leiden University, Leiden, The Netherlands.ORCID 0000-0002-2487-8016
Wendy W J van de SandeErasmus MC, Department of Medical Microbiology and Infectious Diseases, Rotterdam, The Netherlands.ORCID 0000-0002-8652-8783

Funding

Dutch Research CouncilErasmus UniversityH2020 Marie Sklodowska Curie-COFUND program LEaDing Fellows
6 · The paper itself

Abstract

Madurella mycetomatis is the main cause of mycetoma, a chronic granulomatous infection for which currently no adequate therapy is available. To improve therapy, more knowledge on a molecular level is required to understand how M. mycetomatis is able to cause this disease. However, the genetic toolbox for M. mycetomatis is limited. To date, no method is available to genetically modify M. mycetomatis. In this paper, a protoplast-mediated transformation protocol was successfully developed for this fungal species, using hygromycin as a selection marker. Furthermore, using this method, a cytoplasmic-GFP-expressing M. mycetomatis strain was created. The reported methodology will be invaluable to explore the pathogenicity of M. mycetomatis and to develop reporter strains which can be useful in drug discovery as well as in genetic studies.

Indexed as

Hygromycin BMadurellaProtoplastsTransformation, GeneticCinnamatesDrug Resistance, FungalMycetomaCinnamateshygromycin AHygromycin B

Identifiers

PMID38578808
PMCPMC11108199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.